Effect of Alendronate on Bone Mineral Density in Post Menopausal Women with Type 2 Diabetes Mellitus - Sci Forschen

Article Information

Article Type: Research Article

Citation: Sachmechi I, Ahmed S, Joseph J, Reich D, Cardinal L, et al. (2015) Effect of Alendronate on Bone Mineral Density in Post Menopausal Women with Type 2 Diabetes Mellitus. Int J Endocr Metab Disord 1 (1): doi http://dx.doi.org/10.16966/ijemd.103

Copyright: © 2015 Sachmechi I et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Publication history:

 Received date: 10 April, 2015

 Accepted date: 23 March, 2015

 Published date: 28 May, 2015


Authors

Issac Sachmechi^*      Saman Ahmed      Jalaja Joseph      David Reich      Lucien Cardinal      Paul Kim

Division of Endocrinology, Department of Medicine, Mount Sinai Services, Queens Hospital Center, USA

*Corresponding author: Issac Sachmechi, Queens Hospital Center/ Icahn School of Medicine at Sinai, 82-68 164th Street, Department of Medicine, Jamaica, NY 11432, USA, Tel: 718-883-4061; Fax: 718-883-6124; E-mail: Sachmeci@nychhc.org

Abstract

Aim: To perform a retrospective study to determine the effect of Bisphophanates on bone mineral density (BMD) in the late post-menopausal (PM) osteoporatic and osteopenic women with Type 2 Diabetes Mellitus (DM).

Method: In this retrospective case control study, 114 PM diabetic women over age 65 who took alendronate for at least 3 years, 43 of them had osteoporosis and 71 with osteopenia. The efficacy of therapy was measured by comparing a minimum of two BMD studies.

Result: The study (n=114) demonstrated statistical significant BMD gain (+3.1% and +1.9%) at the spine and hip respectively but statistically significant loss of BMD (-9.8%) at forearm (FA). There was statically significant correlation between body mass index (BMI) and BMD, in spine and hip but not in FA. We found negative correlation between A1C and BMD at all 3 sites, with a statically significant correlation observed at FA.

Conclusion: It appears that Bisphosphonates are not effective in preventing bone loss in the FA of diabetic post-menopausal women. In addition bisphosphonates therapy resulted in significant gains of BMD at the spine and hip. A larger study should be done to compare bisphosphonates to other modalities of therapy for osteoporosis in diabetic post menopausal patients.

Keywords

Post menopausal women; Diabetes; Osteoporosis; Alendronate; Bone mineral density


Read Full Article : Here


Published by : Sci Forschen Inc.